# NF-κB Signaling as a Central Driver of Cancer Cachexia

## TL;DR

This paper explores how the NF-κB signaling pathway drives cancer cachexia, a condition causing severe muscle and fat loss, and suggests targeting this pathway could lead to better treatments.

## Contribution

The paper identifies NF-κB as a central driver of cancer cachexia and proposes it as a viable therapeutic target.

## Key findings

- NF-κB signaling promotes muscle wasting, adipose tissue disruption, and metabolic imbalance in cancer cachexia.
- Pharmacologic and nutritional interventions targeting NF-κB show promise in reducing cachexia symptoms.
- Combining NF-κB modulation with other therapies may offer synergistic benefits for treating cancer cachexia.

## Abstract

Cancer cachexia is a debilitating complication that profoundly affects patient quality of life and treatment outcomes, yet its underlying mechanisms remain incompletely understood. Accumulating evidence indicates that persistent inflammation plays a central role in driving muscle wasting, adipose tissue remodeling, and systemic metabolic imbalance. This article provides an integrated overview of how inflammatory signaling coordinates pathological changes across multiple organs, highlighting its contribution to the progression of cachexia. By synthesizing current mechanistic insights, this work aims to clarify key regulatory pathways and identify unifying concepts that advance understanding of disease pathogenesis. These insights may help guide future research and support the development of more effective, mechanism-based therapeutic strategies for cancer cachexia.

Cancer cachexia is a multifactorial metabolic syndrome characterized by progressive skeletal muscle wasting, chronic systemic inflammation, and profound metabolic imbalance. Sustained activation of the nuclear factor κB (NF-κB) signaling pathway lies at the core of its pathogenesis, driving muscle proteolysis, impairing regenerative capacity, disrupting adipose tissue homeostasis, and promoting insulin resistance and anorexia. By transcriptionally regulating catabolic and pro-inflammatory gene programs across skeletal muscle, adipose tissue, the liver, and the central nervous system, NF-κB establishes a self-amplifying inflammatory–metabolic loop that perpetuates tissue wasting and systemic dysfunction. Accumulating preclinical and clinical evidence identifies NF-κB as a viable therapeutic target in cancer cachexia. Pharmacologic inhibitors (e.g., SR12343, DHMEQ), anti-inflammatory strategies (e.g., nonsteroidal anti-inflammatory drugs and IL-6 receptor–targeting antibodies), and nutritional interventions (e.g., omega-3 fatty acids) have shown efficacy in attenuating cachexia-associated inflammation, metabolic dysregulation, and tissue loss. Notably, emerging multimodal approaches integrating NF-κB modulation with metabolic support, chemotherapy, and behavioral interventions demonstrate synergistic benefits. This review integrates current mechanistic insights and therapeutic advances, highlighting NF-κB as a central pathogenic axis and a compelling target for translational intervention in cancer cachexia.